A5038111347- Chronic Lymphocytic Leukemia Research
- Multiple Myeloma Research and Treatments
- Monoclonal and Polyclonal Antibodies Research
- Cancer Treatment and Pharmacology
- Ovarian cancer diagnosis and treatment
- HER2/EGFR in Cancer Research
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Advanced Breast Cancer Therapies
- Lung Cancer Treatments and Mutations
- Lymphoma Diagnosis and Treatment
- Cancer therapeutics and mechanisms
- Metal complexes synthesis and properties
- Cancer-related Molecular Pathways
- Sulfur Compounds in Biology
- Pancreatic and Hepatic Oncology Research
- Cancer Genomics and Diagnostics
- Hepatitis C virus research
- Chemotherapy-induced organ toxicity mitigation
- Bladder and Urothelial Cancer Treatments
- Immunotherapy and Immune Responses
- Ethics in Clinical Research
- Neuroendocrine Tumor Research Advances
- Drug Transport and Resistance Mechanisms
- Chemokine receptors and signaling
Sanofi (United States)
2023-2024
University of California, Davis
2023
Bristol-Myers Squibb (United States)
2017-2022
University of Kansas Medical Center
2013-2020
University of Kansas
2014-2019
Instituto Politécnico Nacional
2019
The University of Kansas Cancer Center
2014-2018
Fox Chase Cancer Center
1990-2017
Dana-Farber Cancer Institute
2017
AbbVie (United States)
2017
Abstract Purpose: Chemokine receptor 1 (CXCR1) is recognized as an actionable selectively expressed by breast cancer stem cells (BCSCs). Reparixin investigational allosteric inhibitor of chemokine receptors and 2 (CXCR1/2), demonstrates activity against BCSCs in human xenografts. This phase Ib clinical trial examined dose, safety, pharmacokinetics paclitaxel plus reparixin therapy, explored effects on patients with metastatic (MBC) (trial registration ID: NCT02001974). Experimental Design:...
Purpose This phase I expansion cohort study evaluated the safety and clinical activity of mirvetuximab soravtansine (IMGN853), an antibody-drug conjugate consisting a humanized anti-folate receptor alpha (FRα) monoclonal antibody linked to tubulin-disrupting maytansinoid DM4, in population patients with FRα-positive platinum-resistant ovarian cancer. Patients Methods epithelial ovarian, fallopian tube, or primary peritoneal cancer received IMGN853 at 6.0 mg/kg (adjusted ideal body weight)...
BACKGROUND Mirvetuximab soravtansine (IMGN853) is an antibody‐drug conjugate that selectively targets folate receptor α (FRα). In this phase 1 dose‐escalation study, the authors investigated IMGN853 in patients with FRα‐positive solid tumors. METHODS Patients received on day of a 21‐day cycle (once every 3 weeks dosing), cycles repeated until experienced dose‐limiting toxicity or progression. Dose escalation commenced single‐patient cohorts for first 4 planned dose levels and then followed...
To characterize folate receptor alpha (FRα) expression in archival and fresh biopsy tumor samples from relapsed ovarian cancer patients.
Ulocuplumab (BMS-936564) is a first-in-class fully human IgG4 monoclonal anti-CXCR4 antibody that inhibits the binding of CXCR4 to CXCL12.This phase Ib/II study aimed determine safety and tolerability ulocuplumab alone in combination with lenalidomide dexamethasone (Arm A), or bortezomib B), patients relapsed/refractory multiple myeloma.Forty-six were evaluated (median age, 60 years; range, 53-67). The median number prior therapies was 3 (range, 1-11), 70% subjects having received ≥3. This...
Cancer stem cells (CSCs) are purported to be responsible for tumor initiation, treatment resistance, disease recurrence, and metastasis. CXCR1, one of the receptors CXCL8, was identified on breast cancer (BC) CSCs. Reparixin, an investigational allosteric inhibitor reduced CSC content human BC xenograft in mice.In this multicenter, single-arm trial, women with HER-2-negative operable received reparixin oral tablets 1000 mg three times daily 21 days before surgery. Primary objectives...
3003 Background: ECHO-204 is an ongoing, open-label, phase 1/2 (P1/2) study of epacadostat (E; potent and selective oral inhibitor the immunosuppressive enzyme indoleamine 2,3-dioxygenase 1) plus PD-1 nivolumab (N) in patients (pts) with advanced cancers (NSCLC, MEL, OVC, CRC, SCCHN, B-cell NHL [including DLBCL], GBM). Preliminary P1/2 safety tolerability outcomes for overall population P2 response select tumor types (SCCHN, CRC) are reported. Methods: In P1 dose escalation, pts received E...
Abstract Background: CD73 is an ectonucleotidase that converts adenosine monophosphate to adenosine, a potent immunosuppressive soluble mediator inhibits the cytotoxic function of CD8+ T cells and natural killer while promoting proliferation cells. BMS-986179 high-affinity antibody enzymatic activity downregulates its expression on tumor Blockade enhanced antitumor anti-PD-1 in preclinical models (Barnhart BC, et al. Cancer Res. 2016;76(14 suppl) [abstract 1476]). Here we describe...
The bone microenvironment (BME) is the main hub of all skeletal related pathological events in osteosarcoma leading to tumor induced destruction, and decreasing overall quality strength. role extra-cellular membrane vesicles (EMVs) as mediators intercellular communication modulating osteosarcoma-BME unknown, needs be investigated. It our hypothesis that osteosarcoma-EMVs contain pro-osteoclastogenic cargo which increases osteoclastic activity, dysregulated remodeling osteosarcoma-BME. In...
UCN-01, a Chk1 inhibitor, abrogates S and G(2) arrest enhances cancer cell killing by DNA-damaging drugs in preclinical models. UCN-01 avidly binds alpha1-acid glycoprotein plasma; whether sufficient drug concentrations are achieved human tumors is unknown. A phase I trial tested the hypothesis that cisplatin-induced cycle (in tumors) at tolerable doses.Patients with advanced received i.v. cisplatin, followed 22 hours later (3-day continuous infusion of 28-day cycle). Platinum was measured...
Aim The aim of the present study was to characterize pharmacokinetics oral proteasome inhibitor, ixazomib, in patients with solid tumours and moderate or severe hepatic impairment, provide posology recommendations. Methods Eligible adults advanced malignancies for which no further effective therapy available received a single dose ixazomib on day 1 pharmacokinetic cycle; normal function, impairment 4 mg, 2.3 mg 1.5 respectively. Blood samples single‐dose characterization were collected over...